Issued 2026-09-25 at $12.12 · now $12.12 (2026-09-25, +0.0% since)
Based on its own history, a month from the 2026-09-25 close, DSGN has typically landed between $8.43 and $16.80 — a range of −30.4% to +38.6% from the issuance price $12.12.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,360 overlapping 1 month windows · 2021-03-26 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.
The cone is anchored at the 2026-09-25 issuance close ($12.12) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where DSGN has typically landed a month from the 2026-09-25 close of $12.12 — the range is history, not a prediction.
- now $12.12 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $12.57 (+3.7%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.69–$14.46
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.43–$16.8
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-07-25 | −71.8% | −71.8% | +12.0% |
| 2023-07-26 | −71.6% | −72.0% | +11.1% |
| 2023-07-21 | −71.6% | −72.1% | +10.6% |
| 3 best | |||
| 2024-06-26 | +62.5% | −1.2% | +62.5% |
| 2024-07-02 | +57.8% | −0.3% | +64.1% |
| 2025-11-04 | +57.4% | +0.0% | +57.4% |
1,360 overlapping windows · 2021-03-26 – 2026-09-25 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-13 | William Arsani | director | Sale | 345,000 @ $5.25 | $1.8M | −11.5% of holding | +9.3% | +79.2% | 2,655,000 | Form 4 · filed 1 day after the trade |
| 2025-08-13 | William Arsani | director | Sale | 217,627 @ $5.25 | $1.1M | −17.9% of holding | +9.3% | +79.2% | 1,000,000 | Form 4 · filed 1 day after the trade |
| 2024-12-18 | Prasad Deepa | director | Sale | 3,806 @ $6.27 | $24K | −16.0% of holding | −16.7% | −37.7% | 20,000 | Form 4 · filed 1 day after the trade |
| 2024-08-09 | William Arsani | director | Sale | 814,874 @ $4.25 | $3.5M | −100.0% of holding | +30.1% | −26.3% | 0 | Form 4 · filed 3 days after the trade |
| 2024-03-25 | Schmid John P. | director | Purchase | 17,809 @ $3.74 | $67K | +194.5% of holding | +0.4% | +34.0% | 26,965 | Form 4 · filed same day |
| 2024-03-25 | Berger Heather A. | director | Purchase | 1,300 @ $3.74 | $5K | ownership Δ n/a | +0.4% | +34.0% | 1,300 | Form 4 · filed same day |
| 2024-03-22 | Schmid John P. | director | Purchase | 9,156 @ $3.62 | $33K | ownership Δ n/a | −0.7% | +30.8% | 9,156 | Form 4 · filed 3 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
32 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | George Simeon | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2026-06-09 | Berger Heather A. | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2026-06-09 | Schmid John P. | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2026-06-09 | Shapiro David | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2026-06-09 | LAPPE RODNEY W | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2026-06-09 | Gover Justin D. | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2026-03-31 | Shapiro David | director | Award / grant | 60,000 | 60,000 | Form 4 |
| 2026-03-31 | Shapiro David | director | Award / grant | 7,500 | 7,500 | Form 4 |
| 2026-01-02 | Gover Justin D. | director | Award / grant | 45,000 | 45,000 | Form 4 |
| 2026-01-02 | Burgess Julie | officer | Award / grant | 150,000 | 150,000 | Form 4 |
| 2026-01-02 | Storgard Chris | officer | Award / grant | 250,000 | 250,000 | Form 4 |
| 2026-01-02 | Jeffries Sean | officer | Award / grant | 375,000 | 375,000 | Form 4 |
| 2026-01-02 | Shah Pratik | director | Award / grant | 750,000 | 750,000 | Form 4 |
| 2025-12-09 | Shah Pratik | director | Award / grant | 525,000 | 525,000 | Form 4 |
| 2025-09-09 | Gover Justin D. | director | Award / grant | 15,833 | 15,833 | Form 4 |
| 2025-09-09 | Gover Justin D. | director | Award / grant | 30,000 | 30,000 | Form 4 |
| 2025-06-10 | Berger Heather A. | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2025-06-10 | George Simeon | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2025-06-10 | LAPPE RODNEY W | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2025-06-10 | William Arsani | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2025-06-10 | Prasad Deepa | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2025-06-10 | Schmid John P. | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2025-05-01 | Storgard Chris | officer | Award / grant | 400,000 | 400,000 | Form 4 |
| 2025-01-02 | Burgess Julie | officer | Award / grant | 135,000 | 135,000 | Form 4 |
| 2025-01-02 | Jeffries Sean | officer | Award / grant | 260,000 | 260,000 | Form 4 |
| 2025-01-02 | Shah Pratik | director | Award / grant | 600,000 | 600,000 | Form 4 |
| 2025-01-02 | LAPPE RODNEY W | director | Award / grant | 25,993 | 25,993 | Form 4 |
| 2024-06-13 | Schmid John P. | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2024-06-13 | George Simeon | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2024-06-13 | Berger Heather A. | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2024-06-13 | William Arsani | director | Award / grant | 19,000 | 19,000 | Form 4 |
| 2024-06-13 | Prasad Deepa | director | Award / grant | 19,000 | 19,000 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.